SureTrader SureTrader SureTrader
Home > Boards > US Listed > Medical - Drugs >

AVEO Pharmaceuticals, Inc. (AVEO)

AVEO RSS Feed
Add AVEO Price Alert      Hide Sticky   Hide Intro
Moderator: mick, ProfitScout
Search This Board:
Last Post: 1/20/2017 8:44:15 AM - Followers: 85 - Board type: Free - Posts Today: 0

AVEO ONCOLOGY, Inc. (AVEO) 


Company website: 
http://www.aveooncology.com/

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).


   

Product pipeline candidates include tivozanib, ficlatuzumab, AV-203 and AV-380.
 
 

AV-380 (GDF-15 Program)

In August 2015, AVEO announced an exclusive, worldwide license agreement with Novartis for the development and commercialization of AVEO’s first-in-class, potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), AV-380, and related antibodies, including modified or derivative forms of any such antibody.

GDF15 is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. Current evidence suggests that a pro- inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

Preclinical data show that inhibition of GDF15 results in a switch from catabolism to anabolism, suggesting that GDF15 inhibition with AV-380 may reverse the effects of cachexia.
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases. It affects some five million individuals in the United States.

Tivozanib

Tivozanib, is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities.

AVEO remains encouraged by the clinical outcomes from its Phase 2 and Phase 3 studies in renal cell carcinoma and the efficacy and tolerability profile that tivozanib may offer to patients suffering from this challenging disease. In addition, promising biomarker results were observed in a Phase 2 study of tivozanib in colorectal cancer.

In August of 2014, AVEO regained all rights to tivozanib. In November 2014, AVEO entered into an option agreement with Ophthotech to investigate tivozanib for the potential treatment of non-oncologic diseases of the eye. In August 2015, AVEO entered into an exclusive license agreement with Pharmstandard OJSC for the development, manufacturing and commercialization of tivozanib in the territories of Russia, Ukraine and the Commonwealth of Independent States (CIS), for all indications excluding ocular conditions. The Company is actively pursuing partnerships in Europe to advance the development and commercialization of tivozanib in solid tumors.

AVEO is interested in collaborating with potential partners who share our vision for cancer drug development and positively impacting patients’ lives. Please contact AVEO [email protected] to discuss partnership opportunities with AVEO’s development pipeline.

Ficlatuzumab

Ficlatuzumab (formerly known as AV-299) is a potent hepatocyte growth factor (HGF) inhibitory antibody that binds to the HGF ligand with high affinity and specificity to inhibit HGF/c-Met biological activities.

AVEO and Biodesix, Inc. have a worldwide agreement to develop and commercialize ficlatuzumab, with VeriStrat®, a serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO and Biodesix are conducting a proof-of-concept study of ficlatuzumab in combination with erlotinib in advanced NSCLC patients selected using BDX001, a serum protein test similar to the VeriStrat test.

An exploratory analysis from AVEO’s Phase 2 study in first-line NSCLC suggested that VeriStrat was prognostic for outcome in the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI)-treated patients and predicted differential treatment benefit for the combination of ficlatuzumab plus TKI over TKI alone. The predictive effect was observed in both progression-free survival and overall survival endpoints
 

AV-203

AVEO scientists have demonstrated through the use of our Human Response Platform™ the importance of ErbB3 in promoting tumor growth. An increasing body of evidence also implicates the activation of ErbB3 in tumorigenesis and the development of resistance to anti-cancer agents. AV-203 is a clinical-stage ErbB3 (HER3) inhibitory antibody candidate designed to inhibit both ligand-dependent and ligand-independent ErbB3 signaling. ErbB3 is a receptor that is typically expressed in many human cancers, and AV-203 has demonstrated preclinical activity in a number of different tumor models including breast, head and neck, lung, ovarian and pancreatic cancers.

AVEO has successfully completed a Phase 1 safety study showing no dose limiting toxicities at maximum dose of 20mg/kg and CLIA (Clinical Laboratory Improvements Amendment) validation has been completed for a biomarker for potential patient selection.


 
www.aveopharma.com
Shares Outstanding   55,070,000
Institutional Ownership  31%
57 Employees
http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-irhome
 
  
One Broadway 14th Floor
Cambridge, MA 02142

Investor Relations
Phone: 617-588-1960
E-mail: [email protected]

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVEO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
AVEO News: Current Report Filing (8-k) 01/12/2017 04:07:25 PM
AVEO News: Current Report Filing (8-k) 01/05/2017 04:52:22 PM
AVEO News: Current Report Filing (8-k) 01/04/2017 04:03:52 PM
AVEO News: Confidential Treatment Order (ct Order) 12/20/2016 02:17:22 PM
AVEO News: AVEO Announces Submission of Responses to the EMA Day 120 List of Questions for Marketing Authorization Application for Tivoz... 11/28/2016 07:00:00 AM
PostSubject
#2197  Sticky Note AVEO and CANbridge Life Sciences Announce Exclusive Licensing ProfitScout 03/21/16 08:31:02 AM
#1839  Sticky Note $AVEO recent news/filings mick 11/17/15 10:42:39 AM
#2414   Not sure what you mean by timing. I Full Contact Yoga 01/20/17 07:50:36 AM
#2413   Welcome back FCY! I love your timing. twistedfreak 01/20/17 07:37:40 AM
#2412   Wow, Bailey truly sucks, facing delisting on multiple Full Contact Yoga 01/19/17 08:37:26 PM
#2411   Hope some good news comes in that lifts rivervalley 01/12/17 08:34:44 PM
#2410   It is time for a 10:1 reverse split Apophis 01/12/17 06:46:22 PM
#2409   The speech the new pres did today had rivervalley 01/11/17 01:19:45 PM
#2408   That would be great, but still at least Full Contact Yoga 01/06/17 11:21:22 AM
#2407   What about the EUSA milestone payment if the twistedfreak 01/06/17 10:39:20 AM
#2406   No milestone payment, slumming under $1 for quite Full Contact Yoga 01/06/17 10:14:28 AM
#2405   INSTITUTIONAL OWNERSHIP HAS SOME NEW POSITIONS, I AM Apophis 01/05/17 10:28:18 AM
#2404   8K not so good... Full Contact Yoga 01/04/17 07:18:38 PM
#2403   Nice to see green Full Contact Yoga 01/04/17 11:35:30 AM
#2402   Aveo Pharmaceuticals (AVEO) mick 12/26/16 10:17:31 PM
#2401   AVEO News: Confidential Treatment Order (ct Order) 12/20/2016 02:17:22 PM mick 12/26/16 10:17:12 PM
#2400   VANGUARD CONTINUES TO LOAD UP SHARES? Apophis 12/21/16 03:42:24 PM
#2399   http://www.nasdaq.com/symbol/aveo/institutional-holdings/decreased Apophis 12/21/16 03:40:00 PM
#2398   Sub $5 is a penny stock, sub $1 Full Contact Yoga 12/20/16 10:32:53 PM
#2397   "AVEO is no penny stock." sunspotter 12/20/16 12:00:14 PM
#2396   sunspotter, that is in ref to your post pennytrader2 12/19/16 03:04:23 PM
#2395   sunspotter, you took the words right of my pennytrader2 12/19/16 03:01:52 PM
#2394   I am waiting to buy back in around Apophis 12/19/16 12:03:42 PM
#2393   Sub .40 likely for this POS Full Contact Yoga 12/19/16 10:07:59 AM
#2392   Any thoughts on EU approval based on the jboatswain 12/18/16 02:41:27 PM
#2391   Garbage. Seems like they're planning the next RS Full Contact Yoga 12/12/16 03:40:42 PM
#2390   Sunspotter: I have to say that the HF Redsox1211 12/07/16 06:53:23 AM
#2389   Most everything under the ask, things don't bode Full Contact Yoga 12/06/16 07:18:17 PM
#2388   Aveo Pharmaceuticals (AVEO) mick 12/04/16 10:11:56 AM
#2387   AVEO News: AVEO Announces Submission of Responses to mick 12/04/16 10:11:41 AM
#2386   AVEO Announces Submission of Responses to the EMA ProfitScout 11/28/16 08:48:47 AM
#2385   AVEO to Present at the 28th Annual Piper ProfitScout 11/22/16 08:40:33 AM
#2384   Looks like the "Trump effect" didn't have any rivervalley 11/20/16 04:31:38 PM
#2383   "My broker seams to think that hedge funds sunspotter 11/15/16 11:17:52 AM
#2382   My broker seams to think that hedge funds Apophis 11/14/16 12:30:21 PM
#2381   thank you, 'AVEO Pharmaceuticals, Inc. (AVEO)' mick 11/10/16 11:37:05 AM
#2380   Phase 3 is a long way off...company continues Full Contact Yoga 11/06/16 11:21:05 AM
#2379   Someone recommended this to me in person and deadjim 11/06/16 02:01:13 AM
#2378   AVEO Oncology Reports Third Quarter 2016 Financial Results ProfitScout 11/04/16 08:46:52 AM
#2377   Uglier by the minute. Glad company has zero Full Contact Yoga 10/31/16 01:48:18 PM
#2376   AVEO News: Current Report Filing (8-k) 10/14/2016 04:29:35 PM mick 10/29/16 12:52:20 PM
#2375   Aveo Pharmaceuticals (AVEO) mick 10/29/16 12:51:04 PM
#2374   Keeps getting worse here. Company should really consider Full Contact Yoga 10/27/16 02:40:48 PM
#2373   $AVEO Technical Analysis http://www.barchart.com/te $Pistol Pete$ 10/19/16 09:04:21 PM
#2372   Apparently the conference later today is being met Full Contact Yoga 10/19/16 11:20:21 AM
#2371   Dumposaurus Rex, company seems to be perfectly happy Full Contact Yoga 10/17/16 12:58:57 PM
#2370   Wow, total POS company. Time for another RS apparently... Full Contact Yoga 10/15/16 09:06:43 PM
#2369   AVEO News: AVEO to Present at the 15th mick 10/13/16 10:37:37 PM
#2368   Aveo Pharmaceuticals (AVEO) mick 10/13/16 10:37:30 PM
#2367   thank you updating/ AVEO mick 10/12/16 12:56:55 PM
#2366   AVEO to Present at the 15th Annual BIO ProfitScout 10/12/16 08:48:28 AM
#2363   AVEO News: Current Report Filing (8-k) 09/30/2016 04:26:39 PM mick 10/01/16 08:21:58 AM
PostSubject